| __timestamp | BioCryst Pharmaceuticals, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 7890000 |
| Thursday, January 1, 2015 | 13047000 | 14456000 |
| Friday, January 1, 2016 | 11253000 | 19218000 |
| Sunday, January 1, 2017 | 13933000 | 27986000 |
| Monday, January 1, 2018 | 29514000 | 47928000 |
| Tuesday, January 1, 2019 | 37121000 | 96388000 |
| Wednesday, January 1, 2020 | 67929000 | 157743000 |
| Friday, January 1, 2021 | 118818000 | 195293000 |
| Saturday, January 1, 2022 | 159371000 | 237374000 |
| Sunday, January 1, 2023 | 213894000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
In the competitive landscape of biotechnology, operational efficiency is paramount. Over the past decade, Blueprint Medicines Corporation and BioCryst Pharmaceuticals, Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A costs, peaking in 2023. In contrast, BioCryst Pharmaceuticals experienced a more modest rise of approximately 2,800% during the same period. This divergence highlights Blueprint's aggressive expansion strategy, possibly reflecting its investment in scaling operations and market penetration. Meanwhile, BioCryst's steadier growth suggests a more conservative approach, potentially focusing on sustainable development. As these companies continue to evolve, their SG&A trends offer valuable insights into their strategic priorities and market positioning.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.